Inivata and Agendia sign agreement for commercialization of RaDaR® MRD liquid biopsy assay in breast cancer

Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe

Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer.

Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata’s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected that the RaDaR assay will be reimbursed and available to clinicians in the US during 2022. Financial and commercial terms were not disclosed.

RaDaR is an innovative, highly sensitive personalized liquid biopsy assay that tracks a set of up to 48 tumor-specific variants in a patient using a simple blood draw, allowing both the detection of residual disease following curative intent or definitive treatment, and early detection of relapse. Proof-of-principle data presented at this year’s AACR Annual Meeting showed RaDaR performed with exceptionally high sensitivity (100% MRD detection) in early-stage breast cancer studies [LINK].

RaDaR is an important addition to Agendia’s precision oncology platform, which includes the MammaPrint® risk of recurrence test and BluePrint® molecular subtyping test. The addition of RaDaR will empower physicians to better triage pre- and post-operative care for patients with breast cancer, and to guide patients back to health while monitoring for early indicators of relapse. The partnership further expands Agendia’s addressable markets and could potentially provide a desperately needed option for more than five million patients with breast cancer across the US and Europe. As Agendia continues to build its brand as a leading women’s health company in breast cancer, the partnership and further addition of genomic tools and capabilities are a natural advancement that will impact not only health outcomes, but overall quality of life for patients living with and beyond breast cancer.

Clive Morris, CEO of Inivata, commented:

“Agendia is a proven leader in providing physicians with precision oncology tools to improve the treatment of patients with breast cancer and we are proud that they have chosen to work with us to commercialize our RaDaR assay. We believe that the use of highly sensitive liquid biopsy approaches to detect MRD has the potential to transform cancer care by providing clinicians with timely, accurate information about whether the disease may have recurred, allowing a window for intervention and the prospect of better outcomes.”

Mark Straley, Chief Executive, Agendia, said:

Inivata is a pioneer in liquid biopsy. The RaDaR assay complements our MammaPrint and BluePrint tests, already used worldwide to provide actionable insights for the prognosis and treatment path in early breast cancer. The partnership with Inivata is a natural progression for Agendia to guide breast cancer care from diagnosis to surgery, treatment to monitoring and beyond, to ensure timely information to manage care. RaDaR will add to our leading market position in breast cancer with a repeat testing model, and give us the opportunity to provide a comprehensive offering for patients at every stage of their journey.

 

Read the full press release and find out more about Inivata